Please login to the form below

Not currently logged in

Jacques Dumas joins Nosopharm scientific advisory board

French biotech's appointments also include Dominique Breilh

Nosopharm has appointed Jacques Dumas and three others to its scientific advisory board to strengthen its preclinical development programme.

Dumas, who has over 20 years of experience of antibiotic R&D, has previously held positions as chief scientific officer at Idenix Pharmaceuticals and VP and head of strategy for AstraZeneca infectious diseases unit.

He is joined on Nosopharm's scientific advisory board by Dominique Breilh, Jean-Michel Molina and Patrice Nordmann.

Dominique Breilh runs the pharmacokinetics and clinical pharmacy laboratory at the University of Bordeaux, France; Jean-Michel Molina is professor of infectious diseases at the University of Paris Diderot; and Patrice Nordmann is professor and director of the molecular microbiology unit at Switzerland's University of Fribourg.

French biotech company Nosopharm, which focus on anti-infective research, said the four appointments reflect a new phase of development for Odilorhabdins, a novel class of antibiotics it is developing.

Philippe Villain-Guillot, CEO of Nosopharm, said: “Dominique Breilh, Jacques Dumas, Jean-Michel Molina and Patrice Nordmann have internationally renowned skills and knowledge, which is a major asset for Nosopharm.

“Their appointments reflect our desire to ramp up our development. Our aim is to run phase I clinical trials starting in 2017 to evaluate a first-generation Odilorhabdin derived from out NOSO-95 molecule.”

19th November 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...